Back to top
more

Cerus (CERS)

(Delayed Data from NSDQ)

$1.29 USD

1.29
1,348,790

+0.05 (3.61%)

Updated Aug 12, 2025 04:00 PM ET

After-Market: $1.28 -0.01 (-0.78%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (145 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Wall Street Analysts Think Cerus (CERS) Could Surge 35%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 35.4% in Cerus (CERS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of 30.00% and 14.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Cerus (CERS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of 10.00% and 20.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Cerus (CERS) Q2 Earnings Expected to Decline

by Zacks Equity Research

Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of -11.11% and 8.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cerus (CERS) Is Up 2.47% in One Week: What You Should Know

by Zacks Equity Research

Does Cerus (CERS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

All You Need to Know About Cerus (CERS) Rating Upgrade to Buy

by Zacks Equity Research

Cerus (CERS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of 33.33% and 2.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cerus (CERS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

The Zacks Analyst Blog Highlights: TTOO, KMDA and CERS

by Zacks Equity Research

The Zacks Analyst Blog Highlights: TTOO, KMDA and CERS

Tirthankar Chakraborty headshot

3 Plasma Stocks to Win Big on FDA's Convalescent EUA

by Tirthankar Chakraborty

Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -

Zacks Equity Research

Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of 10.00% and 0.01%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cerus (CERS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is Cerus (CERS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (CERS) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Cerus (CERS) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Cerus (CERS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of 0.00% and 5.74%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Moving Average Crossover Alert: Cerus

by Zacks Equity Research

Cerus Corporation (CERS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Zacks Equity Research

Will Cerus (CERS) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Cerus Corporation (CERS) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Cerus Corporation (CERS).

Zacks Equity Research

Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of -18.18% and 2.76%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Cerus (CERS) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of -8.33% and 5.50%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Cerus (CERS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of -16.67% and 11.42%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?